As of 2025-12-24, the Intrinsic Value of ALX Oncology Holdings Inc (ALXO) is -9.96 USD. This ALXO valuation is based on the model Peter Lynch Fair Value. With the current market price of 1.40 USD, the upside of ALX Oncology Holdings Inc is -811.45%.
Based on its market price of 1.40 USD and our intrinsic valuation, ALX Oncology Holdings Inc (ALXO) is overvalued by 811.45%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -9.96 - -9.96 | -9.96 | -811.45% |
| P/E | (22.03) - (41.83) | (36.16) | -2682.6% |
| DDM - Stable | (16.00) - (58.87) | (37.44) | -2774.1% |
| DDM - Multi | (18.63) - (54.37) | (27.87) | -2091.1% |
| Market Cap (mil) | 75.91 |
| Beta | 1.09 |
| Outstanding shares (mil) | 54.22 |
| Enterprise Value (mil) | 64.36 |
| Market risk premium | 4.60% |
| Cost of Equity | 9.88% |
| Cost of Debt | 5.00% |
| WACC | 9.19% |